Revenue up and results on the way
Aptamer Group Plc (LSE:APTA), the developer of synthetic binding molecules for life sciences, said in a trading update on 13 July 2026 that it expected revenue of roughly £1.5m for the financial year ended 30 June 2026, up 25% from £1.2m in the previous year. The company attributed the growth to fee-for-service work and its first licensing revenue. On 7 October 2026 it issued a notice of results alongside details of an investor presentation, setting the stage for its audited full-year numbers.
What the company does
Aptamer Group develops Optimer binders, a type of aptamer, which are short synthetic nucleic acid molecules designed to bind to specific targets. These binders can be used in diagnostics, therapeutics, laboratory tools and other applications as an alternative to antibodies. The company earns revenue by carrying out development projects for partners and is increasingly seeking licensing agreements that could generate recurring income from the use of its binders in partner products.
Latest developments
The July update highlighted a sales pipeline of £4.8m at 30 June 2026, up 55% from £3.1m at the half-year update in January. The company also had £0.6m of contracted work scheduled for the 2027 financial year. Management said the group was entering the new year with a larger revenue base, a bigger pipeline and early validation of its licensing strategy.
Programme news has been steady through 2026. In March the company announced the launch of a targeted radiopharmaceutical programme. In June it unveiled a rapid testing programme for fortified foods and published a programme and technical development update, and on 8 July it said it had initiated an Ebola diagnostic test programme. On 20 August 2026 it appointed a joint corporate broker, and on 14 August it announced director fee shares and the grant of options.
Financial picture
Aptamer strengthened its balance sheet in spring 2026. It announced a proposed placing, subscription and retail offer alongside its interim results on 25 March 2026, with the retail offer aiming to raise up to £0.5m, and shareholders approved the related resolutions at a general meeting on 13 April. The company said the April fundraising delivered net proceeds of £4.1m and that it has cash runway into at least 2028. The company has not paid a dividend, which is typical for an early-stage life sciences business that is still loss-making and investing in its technology.
Sector and index context
The market for binding reagents is dominated by antibodies, and aptamer technologies are competing to show advantages in areas such as stability, consistency and speed of development. Licensing deals with diagnostics and pharmaceutical partners are often seen as a route to scalable revenue. Within the FTSE AIM All Share Index, Aptamer is a small biotechnology company whose investment case rests on converting its pipeline into larger, repeatable contracts.
Key risks
Revenue remains small, so the loss of a single project or a delay in pipeline conversion can have a significant effect. Licensing income is at an early stage and may take time to build. Competition from established antibody suppliers and other aptamer developers is a further risk, and future funding needs could lead to dilution if growth is slower than expected.
What to watch next
The audited full-year results for the year to 30 June 2026 will confirm revenue, losses and cash. Investors will look for further licensing agreements, progress on the radiopharmaceutical, food testing and Ebola diagnostic programmes, conversion of the £4.8m pipeline and any update on the path towards breakeven.
_11_18_2026_06_43_20_247880.jpg)





Please wait processing your request...